Description

Summary of preclinical or clinical evidence for an antioxidant therapeutic agent in IBD, presenting data on its effects on mucosal inflammation, barrier function, or disease activity indices.

Figure 11

Diagram

Source Paper

Potential Use of Antioxidant Compounds for the Treatment of Inflammatory Bowel Disease.

Pharmaceuticals (Basel, Switzerland) (2023)

PMID: 37631065

DOI: 10.3390/ph16081150

Cite This Figure

![Figure 11: Summary of preclinical or clinical evidence for an antioxidant therapeutic agent in IBD, presenting data on its effects on mucosal inflammation, barrier function, or disease activity indices.]()

> Source: Alexander V Blagov et al. "Potential Use of Antioxidant Compounds for the Treatment of Inflammatory Bowel D." *Pharmaceuticals (Basel, Switzerland)*, 2023. PMID: [37631065](https://pubmed.ncbi.nlm.nih.gov/37631065/)

<figure>
  <img src="" alt="Summary of preclinical or clinical evidence for an antioxidant therapeutic agent in IBD, presenting data on its effects on mucosal inflammation, barrier function, or disease activity indices." />
  <figcaption>Figure 11. Summary of preclinical or clinical evidence for an antioxidant therapeutic agent in IBD, presenting data on its effects on mucosal inflammation, barrier function, or disease activity indices.<br>  Source: Alexander V Blagov et al. "Potential Use of Antioxidant Compounds for the Treatment of Inflammatory Bowel D." <em>Pharmaceuticals (Basel, Switzerland)</em>, 2023. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37631065/">37631065</a></figcaption>
</figure>

Related Evidence

Curcumin for Ulcerative Colitis (UC)

Grade B · 5 studies

N-Acetyl Cysteine (NAC) for Inflammatory Bowel Disease (IBD) — General

Grade D · 1 studies